Serum inflammatory biomarkers associated with disease severity and response to dupilumab treatment in bullous pemphigoid: a cluster analysis

Dupilumab, a novel therapy targeting the T helper (Th) 2-mediated inflammation, is showing clinical benefits in treating bullous pemphigoid (BP). However, limited research investigated the serum biomarkers that reflect the inflammation alterations throughout the disease course.